Cargando…
Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line
BACKGROUND: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinas...
Autores principales: | Yamauchi, Takahiro, Uzui, Kanako, Nishi, Rie, Shigemi, Hiroko, Ueda, Takanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122765/ https://www.ncbi.nlm.nih.gov/pubmed/25070259 http://dx.doi.org/10.1186/1471-2407-14-547 |
Ejemplares similares
-
Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016) -
Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine
por: Nishi, Rie, et al.
Publicado: (2020) -
Rhabdomyolysis induced by nelarabine
por: Späth, Christian, et al.
Publicado: (2022) -
Nelarabine Associated Myotoxicity and Rhabdomyolysis
por: Haider, Mahnur, et al.
Publicado: (2015) -
Nelarabine in the Treatment of Refractory T-Cell Malignancies
por: Roecker, Andrew M., et al.
Publicado: (2010)